deferiprone has been researched along with aluminum in 26 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (3.85) | 18.7374 |
| 1990's | 13 (50.00) | 18.2507 |
| 2000's | 6 (23.08) | 29.6817 |
| 2010's | 5 (19.23) | 24.3611 |
| 2020's | 1 (3.85) | 2.80 |
| Authors | Studies |
|---|---|
| Dandona, P; Hoffbrand, AV; Jeremy, JY; Kontoghiorghes, GJ | 1 |
| Kontoghiorghes, GJ | 3 |
| Cannata-Andía, JB; Canteros, MA; Díaz-López, JB; Fernández-Martín, JL; Menéndez-Fraga, P | 1 |
| Corbella, J; del Castillo, D; Domingo, JL; Gómez, M; Llobet, JM | 2 |
| Baillod, RA; Barr, J; Kontoghiorghes, GJ | 1 |
| Kontoghiorghes, GJ; Sheppard, LN | 1 |
| Cannata-Andía, JB; Cannata-Ortiz, MJ; Canteros-Piccotto, MA; Fernández-Martín, JL | 1 |
| Domingo, JL | 1 |
| Brown, T; Harris, WR; Li, Y; MacGillivray, RT; Maxwell, A | 1 |
| Berthon, G; Biron, F; Desroches, S | 1 |
| Domingo, JL; Esparza, JL; Gómez, M; Jones, MM; Singh, PK | 1 |
| Blanusa, M; Jones, MM; Kostial, K; Pavlović, D; Prester, L; Singh, PK; Varnai, VM | 1 |
| Albina, ML; Bellés, M; Domingo, JL; Sanchez, DJ | 1 |
| del Castillo, D; Domingo, JL; Esparza, JL; Gómez, M; Hernández, M | 1 |
| Cannata Andía, JB; Fernández Martín, JL; González Suárez, I; Naves Díaz, M | 1 |
| Dong, HJ; Feng, GC; Liu, P; Wu, SD; Yao, YN; Yuan, XY | 1 |
| Chaves, S; Gano, L; Gil, M; Santos, MA | 1 |
| Saljooghi, AS | 1 |
| Khatiwada, CP; Raja, B; Sivakumar, S; Sivasubramanian, J | 2 |
| Khatiwada, CP; Sivakumar, S; Sivasubramanian, J | 2 |
| Ding, Y; Guo, T; Liu, P; Wang, X; Zhang, Y | 1 |
4 review(s) available for deferiprone and aluminum
| Article | Year |
|---|---|
Comparative efficacy and toxicity of desferrioxamine, deferiprone and other iron and aluminium chelating drugs.
Topics: Administration, Oral; Aluminum; Animals; Chelating Agents; Clinical Protocols; Deferiprone; Deferoxamine; Humans; Iron; Iron Chelating Agents; Pyridones | 1995 |
New concepts of iron and aluminium chelation therapy with oral L1 (deferiprone) and other chelators. A review.
Topics: Aluminum; Chelating Agents; Deferiprone; Humans; Iron; Iron Chelating Agents; Pyridones | 1995 |
Chemical, pharmacological, toxicological and therapeutic advances of deferiprone (L1) and other iron and aluminium chelators.
Topics: Aluminum; Animals; Biotransformation; Chelating Agents; Deferiprone; Drug Design; Embryonic and Fetal Development; Humans; Iron; Iron Chelating Agents; Mice; Poisoning; Pyridones; Rabbits; Rats; Structure-Activity Relationship; Therapeutic Equivalency | 1996 |
Adverse effects of aluminium-chelating compounds for clinical use.
Topics: Aluminum; Animals; Antidotes; Chelating Agents; Deferiprone; Deferoxamine; Humans; Pyridones | 1996 |
22 other study(ies) available for deferiprone and aluminum
| Article | Year |
|---|---|
The iron chelators desferrioxamine and 1-alkyl-2-methyl-3-hydroxypyrid-4-ones inhibit vascular prostacyclin synthesis in vitro.
Topics: Aluminum; Animals; Aorta; Arachidonic Acid; Arachidonic Acids; Ascorbic Acid; Calcimycin; Deferiprone; Deferoxamine; Epinephrine; Epoprostenol; Hydrogen Peroxide; Iron; Iron Chelating Agents; Male; Pyridones; Rats; Rats, Inbred Strains | 1988 |
Binding of aluminium to plasma proteins: comparative effect of desferrioxamine and deferiprone (L1).
Topics: Aluminum; Blood Proteins; Deferiprone; Deferoxamine; Humans; Iron Chelating Agents; Kinetics; Protein Binding; Pyridones; Reference Values; Spectrophotometry, Atomic; Temperature; Thermodynamics; Time Factors; Ultrafiltration | 1994 |
Comparative aluminium mobilizing actions of several chelators in aluminium-loaded uraemic rats.
Topics: Aluminum; Animals; Chelating Agents; Citrates; Citric Acid; Deferiprone; Deferoxamine; Female; Injections, Intraperitoneal; Pyridones; Rats; Rats, Sprague-Dawley; Succinates; Succinic Acid; Tissue Distribution; Uremia | 1994 |
Studies of aluminium mobilization in renal dialysis patients using the oral chelator 1,2-dimethyl-3-hydroxypyrid-4-one.
Topics: Adult; Aged; Aluminum; Chromatography, High Pressure Liquid; Deferiprone; Female; Humans; Iron; Iron Chelating Agents; Kidney Failure, Chronic; Male; Middle Aged; Peritoneal Dialysis; Peritoneal Dialysis, Continuous Ambulatory; Pyridones; Renal Dialysis; Spectrophotometry, Atomic | 1994 |
Competition between deferiprone, desferrioxamine and other chelators for iron and the effect of other metals.
Topics: Aluminum; Binding, Competitive; Copper; Deferiprone; Deferoxamine; Iron Chelating Agents; Metals; Pyridones; Spectrophotometry | 1993 |
Four-week oral toxicity study of 1,2-dimethyl-3-hydroxypyrid-4-one (L1) in uremic rats.
Topics: Administration, Oral; Aluminum; Analysis of Variance; Animals; Blood Cells; Blood Chemical Analysis; Body Weight; Brain; Deferiprone; Drinking; Eating; Heart; Iron; Iron Chelating Agents; Liver; Male; Organ Size; Pyridones; Rats; Rats, Wistar; Spleen; Testis; Uremia | 1995 |
Effectiveness of deferiprone (L1) releasing the aluminum bound to plasma proteins in chronic renal failure.
Topics: Aluminum; Blood Proteins; Chelating Agents; Deferiprone; Humans; In Vitro Techniques; Kidney Failure, Chronic; Protein Binding; Pyridones | 1996 |
Kinetic studies on the removal of iron and aluminum from recombinant and site-directed mutant N-lobe half transferrins.
Topics: Alanine; Aluminum; Animals; Arginine; Binding Sites; Cell Line; Cricetinae; Deferiprone; Humans; Iron; Kidney; Kinetics; Lysine; Macromolecular Substances; Mutagenesis, Site-Directed; Peptide Fragments; Pyridones; Recombinant Proteins; Transferrin | 1998 |
Aluminum speciation studies in biological fluids. Part 5. A quantitative investigation of A1(III) complex equilibria with desferrioxamine, 2,3-dihydroxybenzoic acid, Tiron, CP20 (L1), and CP94 under physiological conditions, and computer-aided assessment
Topics: 1,2-Dihydroxybenzene-3,5-Disulfonic Acid Disodium Salt; Aluminum; Animals; Body Fluids; Chelating Agents; Computer Simulation; Deferiprone; Deferoxamine; Humans; Hydroxybenzoates; Indicators and Reagents; Inflammation; Iron Chelating Agents; Ligands; Pyridones; Rabbits; Rats; Reproducibility of Results | 1999 |
Chelation therapy in aluminum-loaded rats: influence of age.
Topics: Aging; Aluminum; Animals; Antidotes; Chelating Agents; Chelation Therapy; Deferiprone; Deferoxamine; Male; Pyridines; Pyridones; Rats; Rats, Sprague-Dawley; Tissue Distribution | 1999 |
Chelation of aluminium by combining DFO and L1 in rats.
Topics: Aluminum; Animals; Chelating Agents; Deferiprone; Deferoxamine; Dose-Response Relationship, Drug; Drug Synergism; Drug Therapy, Combination; Female; Iron; Iron Chelating Agents; Pyridones; Rats; Rats, Wistar | 2000 |
Evaluation of the protective activity of deferiprone, an aluminum chelator, on aluminum-induced developmental toxicity in mice.
Topics: Abnormalities, Drug-Induced; Administration, Oral; Aluminum; Animals; Body Weight; Bone and Bones; Deferiprone; Female; Fetal Growth Retardation; Iron Chelating Agents; Male; Mice; Organ Size; Pyridones; Time Factors | 2000 |
Age-Related differences on aluminium mobilization by chelating agents in aluminium-loaded uraemic rats.
Topics: Administration, Oral; Aging; Aluminum; Aluminum Compounds; Animals; Anthelmintics; Chelating Agents; Deferiprone; Deferoxamine; Drug Therapy, Combination; Injections, Subcutaneous; Male; Nitrates; Pyridones; Rats; Rats, Sprague-Dawley; Uremia | 2000 |
[Effect of desferrioxamine and deferiprone on osteocalcin secretion in osteoblast-type cells].
Topics: Aluminum; Animals; Bone Neoplasms; Calcitriol; Cattle; Chelating Agents; Culture Media; Deferiprone; Deferoxamine; Dose-Response Relationship, Drug; Humans; Osteoblasts; Osteocalcin; Osteosarcoma; Pyridones; Secretory Rate; Serum Albumin, Bovine; Tumor Cells, Cultured | 2003 |
The efficacy of deferiprone on tissues aluminum removal and copper, zinc, manganese level in rabbits.
Topics: Aluminum; Animals; Body Weight; Copper; Deferiprone; Manganese; Pyridones; Rabbits; Spectrum Analysis; Zinc | 2005 |
Bifunctional 3-hydroxy-4-pyridinone derivatives as potential pharmaceuticals: synthesis, complexation with Fe(III), Al(III) and Ga(III) and in vivo evaluation with 67Ga.
Topics: Aluminum; Animals; Deferiprone; Drug Design; Gallium; Gallium Radioisotopes; Iron; Mice; Molecular Structure; Pyridones; Tissue Distribution | 2005 |
Chelation of aluminum by combining deferasirox and deferiprone in rats.
Topics: Aluminum; Animals; Benzoates; Chelating Agents; Deferasirox; Deferiprone; Iron; Male; Pyridones; Rats; Rats, Wistar; Triazoles | 2012 |
FT-Raman study of deferoxamine and deferiprone exhibits potent amelioration of structural changes in the liver tissues of mice due to aluminum exposure.
Topics: Aluminum; Animals; Chelating Agents; Deferiprone; Deferoxamine; Liver; Male; Mice; Pyridones; Spectroscopy, Fourier Transform Infrared | 2014 |
FTIR study of protective action of deferoxamine and deferiprone on the kidney tissues of aluminum loaded mice.
Topics: Aluminum; Animals; Chelating Agents; Deferiprone; Deferoxamine; Kidney; Male; Mice; Protective Agents; Pyridones; Spectroscopy, Fourier Transform Infrared | 2014 |
Studies the alterations of biochemical and mineral contents in bone tissue of mus musculus due to aluminum toxicity and the protective action of desferrioxamine and deferiprone by FTIR, ICP-OES, SEM and XRD techniques.
Topics: Aluminum; Animals; Bone and Bones; Deferiprone; Deferoxamine; Iron Chelating Agents; Male; Mice; Microscopy, Electron, Scanning; Minerals; Protective Agents; Pyridones; Spectroscopy, Fourier Transform Infrared; X-Ray Diffraction | 2014 |
Protective effects of desferrioxamine and deferiprone on the spleen tissue of aluminum intoxicated mice: A Fourier transform infrared spectroscopy study.
Topics: Aluminum; Animals; Deferiprone; Deferoxamine; Male; Mice; Protective Agents; Pyridones; Spectroscopy, Fourier Transform Infrared; Spleen | 2014 |
Taurine and deferiprone against Al-linked apoptosis in rat hippocampus.
Topics: Aluminum; Alzheimer Disease; Animals; Apoptosis; bcl-2-Associated X Protein; Caspase 3; Chelating Agents; Deferiprone; Hippocampus; Male; Proto-Oncogene Proteins c-bcl-2; Rats; Rats, Wistar; Taurine | 2023 |